Molecular obesity therapies advance, but precision prescribing remains largely unproven
A 2026 review finds that multi-agonist obesity drugs can produce substantial weight loss, but biomarker and pharmacogenomic tools are not ...
A 2026 review finds that multi-agonist obesity drugs can produce substantial weight loss, but biomarker and pharmacogenomic tools are not ...
A large retrospective cohort found that hormone-therapy use was associated with greater, sustained semaglutide weight loss in midlife women, while ...
A new narrative review finds that GLP-1 receptor agonists like semaglutide and tirzepatide are safe and effective for weight loss ...
A new narrative review finds that GLP-1 receptor agonists and tirzepatide deliver cardiovascular and kidney benefits beyond glucose control, with ...
A new opinion article argues that inflammation may be the missing link explaining both the potential suicide risk and the ...
A new case report describes two women with recurrent depressive disorder who experienced severe panic attacks shortly after tirzepatide injections, ...
A new commentary in the Journal of Clinical Sleep Medicine argues that hours-per-night metrics fundamentally misrepresent how well patients actually ...
A meta-analysis of 37 phase 3 trials involving more than 50,000 adults finds that weight loss explains about 76 percent ...
New research presented at the 11th UK Congress on Obesity in Sheffield shows GLP-1 medications are reshaping treatment while behavioural ...
An indirect treatment comparison of the SURMOUNT-1 and STEP 1 trials finds tirzepatide 10 and 15 mg delivers greater weight ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine